Finance

Beta
Lists
000100:KRX
Yuhan Corp
₩77,200.00
+1.05%
(+800.00) 1D
Jun 12, 3:30:06 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 000100...
Open
₩77,700
High
₩79,000
Low
₩77,000
Mkt. cap
6.22T
Avg. vol.
328.97K
Volume
0.00
Dividend
0.78%
Quarterly dividend
₩150
Ex-dividend date
Feb 26, 2026
P/E ratio
27.10
52-wk high
₩136,400
52-wk low
₩71,700
EPS
₩2,848
Shares outstanding
79.65M
No. of employees
2K
Open
₩77,700
High
₩79,000
Low
₩77,000
Mkt. cap
6.22T
Avg. vol.
328.97K
Volume
0.00
Dividend
0.78%
Quarterly dividend
₩150
Ex-dividend date
Feb 26, 2026
P/E ratio
27.10
52-wk high
₩136,400
52-wk low
₩71,700
EPS
₩2,848
Shares outstanding
79.65M
No. of employees
2K
News stories
From sources across the web
Profile
Yuhan Corporation is a South Korean pharmaceutical and chemical company headquartered in Daebang-dong, Dongjak-gu, Seoul. It was established in 1926 by New Il-han and has been listed on the Korea Stock Exchange since 1962. Yuhan is one of the top Korean pharmaceutical companies, along with Celltrion, Samsung Biologics, GC Pharma, and Hanmi Pharmaceutical. Wikipedia
About Yuhan Corp
CEOWook Je Cho
Employees2.09K
Founded1926
Headquarters-
SectorPharmaceutical industry
Websiteyuhan.co.kr
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
578.99B
570.01B
546.07B
526.78B
Cost of goods sold
380.07B
401.57B
333.27B
377.63B
Cost of revenue
380.07B
401.57B
333.27B
377.63B
Research and development expenses
48.10B
45.94B
78.04B
47.24B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
94.81B
94.69B
103.16B
88.43B
Operating expense
149.06B
146.43B
185.79B
140.37B
Total operating expenses
529.13B
548.00B
519.05B
518.00B
Operating income
49.86B
22.01B
27.02B
8.78B
Other non operating income
-2.59B
-2.09B
-4.58B
231.25M
EBT including unusual items
51.59B
35.18B
120.91B
28.76B
EBT excluding unusual items
58.20B
34.24B
112.36B
26.45B
Income tax expense
7.59B
14.01B
10.77B
5.39B
Effective tax rate
14.70%
39.83%
8.91%
18.75%
Other operating expenses
2.64B
1.68B
3.00B
1.94B
Net income
45.53B
25.28B
114.43B
27.04B
Net profit margin
7.86%
4.44%
20.96%
5.13%
Earnings per share
617.00
348.00
1.53K
372.00
Interest and investment income
2.01B
2.11B
2.13B
2.35B
Interest expense
-4.05B
-3.99B
-3.91B
-3.86B
Net interest expenses
-2.04B
-1.88B
-1.77B
-1.51B
Depreciation and amortization charges
2.30B
2.12B
962.24M
1.52B
EBITDA
67.56B
40.00B
44.17B
27.88B
Gain or loss from assets sale
240.96M
9.44M
-9.65B
15.64M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer